Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash Flows From Operating Activities:
Net loss	$ (51,070)	$ (46,632)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	19,493	21,235
Stock-based compensation	9,754	8,490
Accretion of debt discount, recorded to interest expense on 2018 Convertible Notes (Note 14)	4,246	3,895
Amortization of deferred financing costs, recorded to interest expense on 2018 Convertible Notes (Note 14)	521	493
Bad debt (recovery) expense	(15)	11
Impairment of intangible assets (Note 3(f))	0	7,160
Unrealized foreign currency exchange loss (gain)	(155)	435
Research and development expense recognized for the value of stock issued in connection with milestone achievement (Note 16(b)(xii))	2,419	0
Change in fair value of contingent consideration related to the EVOMELA and Talon acquisitions (Note 9)	1,249	565
Changes in operating assets and liabilities:
Accounts receivable, net	(12,040)	22,537
Other receivables	5,571	(8,008)
Inventories	(6,768)	2,127
Prepaid expenses	804	(133)
Deferred tax assets	0	(147)
Other assets	(2,095)	(1,398)
Accounts payable and other accrued obligations	(6,595)	(5,638)
Accrued payroll and benefits	(451)	(1,286)
Drug development liability	(526)	(1,385)
Acquisition related contingent obligations	(1,300)	0
Deferred revenue	(1,417)	359
Deferred tax liability	(40)	89
Other long-term liabilities	1,321	874
Net cash (used in) provided by operating activities	(37,094)	3,643
Cash Flows From Investing Activities:
Proceeds from sale of available-for-sale securities	0	3,061
Redemption of mutual funds	(1)	0
Purchases of property and equipment	(61)	(212)
Net cash (used in) provided by investing activities	(62)	2,849
Cash Flows From Financing Activities:
Proceeds from exercise of stock options	190	1,482
Proceeds from sale of stock under employee stock purchase plan	383	335
Purchase and retirement of restricted stock to satisfy employees' tax liability at vesting	(829)	(629)
Payment of contingent consideration related to EVOMELA acquisition (Note 9(b))	(4,700)	0
Proceeds from common shares sold under an at-the-market-issuance sales agreement (Note 18)	73,869	0
Dividends paid upon conversion of Series E Convertible Voting Preferred Stock (Note 18)	(6)	0
Net cash provided by financing activities	68,907	1,188
Effect of exchange rates on cash and equivalents	113	(1,095)
Net increase in cash and cash equivalents	31,864	6,585
Cash and cash equivalents—beginning of period	139,741	129,942
Cash and cash equivalents—end of period	171,605	136,527
Supplemental disclosure of cash flow information:
Cash paid for income taxes	11	332
Cash paid for interest	$ 1,650	$ 1,650